• 1. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369

Recent Advances in the Study of 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine (CAS: 867285-07-2)

The compound 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine (CAS: 867285-07-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its benzothiazole core and ethyl-substituted tetrahydro structure, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

One of the key areas of investigation has been the synthesis and optimization of 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel, high-yield synthetic route that improves both the efficiency and scalability of production. The study highlighted the importance of optimizing reaction conditions to minimize byproducts and enhance purity, which is critical for pharmaceutical applications. The authors also explored the compound's stability under various conditions, providing essential data for formulation development.

Pharmacological evaluations of 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine have revealed its potential as a modulator of central nervous system (CNS) targets. In vitro and in vivo studies have demonstrated its affinity for specific neurotransmitter receptors, suggesting possible applications in neurodegenerative diseases and psychiatric disorders. For instance, a recent preclinical study indicated that the compound exhibits neuroprotective effects in models of Parkinson's disease, potentially through its interaction with dopaminergic pathways. These findings underscore the therapeutic promise of this molecule and warrant further investigation.

Another significant development is the exploration of 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine as a scaffold for drug discovery. Researchers have synthesized and evaluated a series of derivatives to enhance its pharmacological profile. Structure-activity relationship (SAR) studies have identified key modifications that improve bioavailability and target selectivity. These efforts have led to the identification of lead compounds with improved efficacy and reduced off-target effects, paving the way for future clinical trials.

In conclusion, the recent research on 6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine (CAS: 867285-07-2) highlights its potential as a versatile and pharmacologically active molecule. Advances in synthesis, pharmacological evaluation, and derivative development have expanded our understanding of its therapeutic applications. Continued research in this area is expected to yield novel drug candidates with significant clinical impact.

• 58482-94-3(2-BENZOTHIAZOLAMINE, 4,5,6,7-TETRAHYDRO-5,7-DIMETHYL-)
• 55895-83-5(5,6-Dihydrocyclopenta[d][1,2,3]triazol-2(4H)-amine hydrobromide)
• 867285-14-1(4,4-dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 27460-91-9(2-Benzothiazolamine, 4,5,6,7-tetrahydro-5,5,7-trimethyl-)
• 81779-11-5(2-Amino-6-tert-butyl-4,5,6,7-tetrahydrobenzothiazole)
• 7496-50-6(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 2933-29-1(4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 15951-21-0(4,5,6,7-Tetrahydro-benzothiazol-2-ylamine hydrochloride)
• 72029-36-8((1r,3as,3br,5as,10as,10bs,12ar)-10a,12a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-1h-cyclopenta[7,8]phenanthro[2,3-d][1,3]thiazol-8-amine)
• 867286-03-1(2-BENZOTHIAZOLAMINE, 4,5,6,7-TETRAHYDRO-6-PENTYL-)